^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR1247 (MicroRNA 1247)

    i
    Other names: MIR1247, MicroRNA 1247, Hsa-MiR-1247-5p, Hsa-Mir-1247, MIMAT0005899, MIMAT0022721, MI0006382, Mir-1247, MIRN1247, MIR1247
    Associations

    News

    Trials
    4ms
    MicroRNA expression dynamics in mouse liver at different stages of Echinococcus multilocularis infection. (PubMed, BMC Genomics)
    Overall, our investigation elucidates the temporal dynamic changes in host miRNAs and their potential target genes at the early, middle and late stages of E. multilocularis infection, which allows us to understand the roles of miRNAs in host-parasite interactions throughout infection and provides a reference for further studies of molecular pathogenesis and new drug or vaccine targets for control of AE.
    Preclinical • Journal
    |
    MAPK1 (Mitogen-activated protein kinase 1) • TGFB1 (Transforming Growth Factor Beta 1) • JAG1 (Jagged Canonical Notch Ligand 1) • MIR122 (MicroRNA 122) • MIR1247 (MicroRNA 1247) • MIR149 (MicroRNA 149)
    6ms
    Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate. (PubMed, Urol Ann)
    However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.
    Journal
    |
    MIR1246 (MicroRNA 1246) • MIR1247 (MicroRNA 1247) • MIR127 (MicroRNA 127) • MIR191 (MicroRNA 191)
    6ms
    Opposing mechanisms by which miRNAs mediate distinct Nrf1 and Nrf2 regulation of epithelial-mesenchymal transition in hepatocellular carcinoma. (PubMed, RNA Biol)
    By contrast, Nrf2 inhibits the miR-1247-5p expression, relieving its inhibitory effect on MMP15 and MMP17 to promote the EMT. Collectively, these results demonstrate that the EMT of HCC is likely prevented by Nrf1 via the miR-3187-3p signalling to SNAI1-CDH1/2 axis, but conversely promoted by Nrf2 through the miR-1247-5p-MMP15/17 signalling axis.
    Journal
    |
    CDH1 (Cadherin 1) • MMP17 (Matrix Metallopeptidase 17) • NRF1 (Nuclear Respiratory Factor 1) • CDH2 (Cadherin 2) • MIR3187 (MicroRNA 3187) • SNAI1 (Snail Family Transcriptional Repressor 1) • MIR1247 (MicroRNA 1247) • MMP7 (Matrix metallopeptidase 7)
    11ms
    Visualization of Cancer Cell-Derived Exosome-Induced Fibroblast Phenotypic Transformation. (PubMed, Anal Chem)
    Both sensors showed high sensitivity and good selectivity, with detection limits of 4.94 and 6.61 pM for miR-1247-3p and FAP mRNA, respectively. Moreover, two sensors allowed us to image living cell postinvasion of tumor-derived exosomes, facilitating visual monitoring of fibroblast phenotype transformation and uncovering new perspectives on cancer metastasis development.
    Journal
    |
    MIR1247 (MicroRNA 1247)
    12ms
    Tumour protein p53-activated lncRNA PGM5-AS1 suppresses lung cancer growth and stemness by targeting R-spondin1 via microRNA-1247-5p. (PubMed, Arch Physiol Biochem)
    Elevating PGM5-AS1 or repressing miR-1247-5p restrained LC cell growth and stemness, which were reversed by depression of RSPO1. This study conveys that TP53-elevated PGM5-AS1 mediates miR-1247-5p to target RSPO1, thereby inhibiting LC growth and stemness, representing a novel avenue for LC therapy.
    Journal
    |
    TP53 (Tumor protein P53) • MIR1247 (MicroRNA 1247) • RSPO1 (R-Spondin 1)
    12ms
    Differential Expression of miRNAs Between Young-Onset and Late-Onset Indian Colorectal Carcinoma Patients. (PubMed, Noncoding RNA)
    Our analysis revealed metabolic reprogramming, downregulation of anoikis-regulating pathways, and changes in tissue morphogenesis, potentially leading to anchorage-independent growth and progression of epithelial-mesenchymal transition (EMT). Upregulated targets include proteins present in the basal part of intestinal epithelial cells and genes whose expression is known to correlate with invasion and poor prognosis.
    Journal
    |
    MSI (Microsatellite instability) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway) • MIR1247 (MicroRNA 1247) • MIR148A (MicroRNA 148a) • MIR326 (MicroRNA 326)
    1year
    Integrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD. (PubMed, Discov Oncol)
    In vitro tests showed that CHAF1B suppression decreased LUAD's migration, invasion, proliferation, and glycolysis. Overall, CHAF1B may be an innovative biomarker and therapeutic target for LUAD.
    Journal • IO biomarker
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • MIR1247 (MicroRNA 1247) • MIR145 (MicroRNA 145)
    1year
    miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer. (PubMed, PLoS One)
    The effectiveness of chemotherapy involving 5-fluorouracil and cisplatin (DDP) for the treatment of colorectal cancer (CRC) is often limited due to the emergence of drug resistance. By modulating CCND1, miR-1247-3p can effectively reduce drug resistance and promote apoptosis in CRC cells, suggesting that miR-1247-3p could potentially reduce chemotherapy resistance by targeting CCND1. These results highlight the pivotal role of miR-1247-3p in reducing chemotherapy resistance through the inhibition of CCND1, providing insight into a promising therapeutic strategy for overcoming CRC resistance.
    Journal
    |
    CCND1 (Cyclin D1) • MIR1247 (MicroRNA 1247)
    |
    CCND1 expression
    |
    cisplatin • 5-fluorouracil
    1year
    Analysis of Methylation of Tumor-suppressive miRNAs and KRAS/TP53 Mutations in Pancreatic Juice. (PubMed, Anticancer Res)
    Analyzing the methylation of miR-1247 in addition to KRAS and TP53 mutations in pancreatic juice may be useful to distinguish PC from PanIN/IPMN.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MIR200A (MicroRNA 200a) • MIR1247 (MicroRNA 1247)
    |
    TP53 mutation • KRAS mutation • TP53 mutation + KRAS mutation • KRAS mutation + TP53 mutation
    over1year
    The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review. (PubMed, Biomed Res Int)
    Curcumin exerts its anticancer effects on urogenital neoplasms by upregulating tumor suppressor microRNAs (miR-143, miR-145, miR-Let-7, miR-101, miR-3127, miR-3178, miR-1275, miR-3198, miR-1908, miR-770, miR-1247, miR-411, miR-34a, miR-383, miR-708, miR-483, miR-199a, miR-335, miR-503, miR-10b, miR-551a, miR-9, miR-203, miR-7110, miR-29b, and miR-126) and downregulating oncogenic microRNAs (miR-21, miR-210, miR-382, miR-654, miR-494, miR-193b, miR-671, miR-222, miR-23b, miR-664, miR-183, miR-214, miR-320a, miR-23a, miR-30a, miR-320d, miR-1285, miR-32, miR-181a, miR-205, miR-216a, miR-1246, and miR-106b). Cell proliferation is inhibited, and cell apoptosis is induced by curcumin in different urogenital cancers through suppressing oncogenic microRNAs or provoking tumor suppressor microRNAs.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR1246 (MicroRNA 1246) • MIR126 (MicroRNA 126) • MIR143 (MicroRNA 143) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR216A (MicroRNA 216a) • MIR23A (MicroRNA 23a) • MIR23b (MicroRNA 23b) • MIR320A (MicroRNA 320a) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR503 (MicroRNA 503) • MIR664A (MicroRNA 664a) • MIR106B (MicroRNA 106b) • MIR10B (MicroRNA 10b) • MIR1247 (MicroRNA 1247) • MIR127 (MicroRNA 127) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIR30A (MicroRNA 30a) • MIR3178 (MicroRNA 3178) • MIR383 (MicroRNA 383) • MIR483 (MicroRNA 483) • MIR671 (MicroRNA 671) • MIR708 (MicroRNA 708)
    over1year
    PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer. (PubMed, Int J Biol Sci)
    To study the properties of circATIC, sanger sequencing, agarose gel electrophoresis and treatment with RNase R/Actinomycin D were utilized. Finally, circATIC promotes RCC2 expression to enhance Epithelial-Mesenchymal Transition (EMT) progression and activate JNK signal pathway, thus strengthening DDP resistance in BLca cells. Our study demonstrated that circATIC promoted BLca progression and DDP resistance, and could serve as a potential target for BLca treatment.
    Journal
    |
    PTBP1 (Polypyrimidine Tract Binding Protein 1) • MIR1247 (MicroRNA 1247)
    |
    cisplatin • dactinomycin
    2years
    Gallic acid attenuates metastatic potential of human colorectal cancer cells through the miR-1247-3p-modulated integrin/FAK axis. (PubMed, Environ Toxicol)
    Consistently, the in vivo xenograft model showed that GA administration inhibited tumor growth and liver metastasis derived from DLD-1 cells. Collectively, our findings indicated that GA inhibited the metastatic capabilities of CRC cells, which may result from the suppression of integrin/FAK axis mediated by miR1247-3p.
    Journal • Metastases
    |
    TLN1 (Talin 1) • MIR1247 (MicroRNA 1247)